Fig. 6From: Efficacy and safety of baricitinib in treatment of systemic lupus erythematosus: a systematic review and meta-analysisA forest plot displaying the prevalence of No new BILAG A and no more than one new BILAB B disease activity score in the baricitinib group versus the placebo group. (A) before sensitivity analysis. (B) after sensitivity analysisBack to article page